Retatrutide vs CagriSema

Retatrutide is one peptide activating GIP, GLP-1 and glucagon receptors. CagriSema combines the amylin analogue cagrilintide with semaglutide, a GLP-1 receptor agonist. Both have substantial placebo-controlled human weight-loss findings, including separate trials with type 2 diabetes, but no direct randomized comparison in the selected sources establishes which is more effective or safer. Both remain investigational as of October 2026.

Research reviewed October 15, 2026. Educational information only.

One triple agonist and a two-peptide combination

Retatrutide activates receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1 (GLP-1) and glucagon within one molecule. CagriSema combines two molecules: cagrilintide, which acts at amylin and calcitonin receptors, and semaglutide, which acts at the GLP-1 receptor. Amylin is a hormone involved in satiety and glucose regulation, and cagrilintide was developed as a longer-acting analogue. These are different ways to engage several metabolic signals.

The CagriSema trials tested a defined fixed-dose combination delivered in a dual-chamber pen. Their findings belong to that product and protocol, including investigator-directed changes when tolerability required them. A blend of separately sourced materials cannot inherit the same evidence merely by listing both ingredient names. Likewise, retatrutide’s triple-receptor activity does not predict the size of its effect relative to the two-peptide combination.

The main differences

The obesity trials without diabetes

TRIUMPH-1 randomized 2,339 adults with obesity without diabetes to retatrutide or placebo for 80 weeks. With the program’s diet and activity support, mean weight reductions were 17.6%, 23.7% and 25.0% in the assigned retatrutide groups, versus 3.9% with placebo. The two higher groups had additional losses of 19.8 and 21.0 percentage points over placebo (P<0.001 for each), using the treatment-regimen analysis.

REDEFINE 1 randomized 3,417 adults without diabetes who had obesity, or overweight with an obesity-related complication, to CagriSema, semaglutide, cagrilintide or placebo for 68 weeks. All groups received lifestyle support. Mean weight reductions were 20.4% with CagriSema and 3.0% with placebo, an adjusted difference of 17.3 percentage points (95% CI 16.6–18.1). Semaglutide and cagrilintide alone produced 14.9% and 11.5% reductions under the same principal analysis. Those component comparisons directly test the added effect within this trial; none compares with retatrutide.

The difference between a 25.0% average in one study and 20.4% in another is a numerical cross-study observation. The twelve-week difference in follow-up, eligibility, protocol and handling of missing measurements prevents it from establishing relative efficacy.

Analysis assumptions and the separate diabetes populations

The main obesity figures above estimate effects while accounting for treatment stopping and other specified events: the papers call these the treatment-regimen or treatment-policy estimands. CagriSema’s REDEFINE 1 trial also reports a 22.7% reduction versus 2.3% with placebo under the trial-product analysis, which assumes continued assigned treatment without other weight intervention. Retatrutide’s sponsor reported 28.3% under its efficacy analysis. Estimates that assume continued treatment answer a different question from estimates that include outcomes after treatment stops; their percentages are not interchangeable.

The diabetes trials enrolled separate populations. TRIUMPH-2 randomized 1,152 adults with obesity and type 2 diabetes; 92% were using oral glucose-lowering medicine at baseline. At 80 weeks, the highest retatrutide group lost 18.8% on average versus 5.1% with placebo, with an adjusted additional loss of 13.8 percentage points (95% CI 11.8–15.8).

REDEFINE 2 randomized 1,206 adults with type 2 diabetes, a body mass index (BMI) of at least 27 and HbA1c of 7–10%. BMI relates weight to height, while HbA1c reflects blood-glucose exposure over preceding weeks and months. They were assigned to CagriSema or placebo alongside lifestyle support. Participants used lifestyle measures alone or up to three stable oral glucose medicines at entry. At 68 weeks, mean weight fell 13.7% versus 3.4%, an additional 10.4 percentage points (95% CI 9.5–11.2) under the treatment-policy analysis. These different studies establish effects against their own controls; they cannot identify whether retatrutide or CagriSema is better for the same person with diabetes.

The two ingredients have separate pharmacokinetics

Retatrutide’s early phase 1b study in adults with type 2 diabetes estimated an elimination half-life of approximately six days after subcutaneous administration. That is an estimate for the circulating retatrutide molecule in that early trial.

In the 20-week cagrilintide–semaglutide coadministration study, researchers randomized 96 adults with overweight or obesity; 95 received treatment. Cagrilintide and semaglutide were measured separately in plasma. Cagrilintide half-life ranged 159–195 hours across groups and semaglutide 145–165 hours. These are ranges of group estimates, not confidence intervals or one combined CagriSema half-life. Cagrilintide did not materially change semaglutide exposure or elimination in that study.

All three peptides therefore have elimination on a timescale of days, but that observation supplies no ranking of weight reduction. Receptor action, product formulation, clinical tolerability and treatment continuation also influence outcomes. No exposure curve can substitute for a direct outcome comparison.

What the separate safety reports show

In REDEFINE 1, digestive adverse events affected 79.6% of CagriSema recipients and 39.9% with placebo. Most were transient and mild or moderate, but 5.9% of CagriSema recipients and 3.5% of placebo recipients permanently stopped treatment because of adverse events. Gallbladder events were also more frequent with the combination (4.1% versus 1.0%). Serious events occurred in 9.8% versus 6.1%; a reported event does not by itself establish that the drug caused it.

In REDEFINE 2, digestive events occurred in 72.5% with CagriSema and 34.4% with placebo. Because of adverse events, 8.4% of CagriSema recipients and 3.0% of placebo recipients stopped treatment. The presence of diabetes and background medicines matters for glucose-related harms, so these rates need their own population context.

Retatrutide’s TRIUMPH-1 abstract identifies digestive events as most common without a complete safety table. In the separate TRIUMPH-2 diabetes trial, diarrhea occurred in 34% of the highest group versus 13% with placebo, and nausea in 28% versus 8%. Hypotension (low blood pressure) and dysesthesia (altered or unpleasant skin sensation) were more frequent with retatrutide. These observations identify specific tolerability issues to follow, but the studies have no shared randomization between retatrutide and CagriSema. They cannot establish a safer choice.

What remains unresolved in October 2026

The published results establish substantial additional weight loss versus placebo for each treatment under its study conditions. CagriSema also has direct comparisons with its own ingredients, which help evaluate the combination’s added effect. That evidence does not resolve a comparison with retatrutide, and counting positive trials cannot replace a common outcome measured in a common randomized population.

Current manufacturer information still identifies both retatrutide and CagriSema as investigational. Recent sponsor announcements add development information, but a preliminary trial summary needs to retain its particular comparator, population and analysis assumptions. The retatrutide profile, CagriSema profile and tirzepatide versus CagriSema comparison provide related context without treating unlike trials as a direct ranking.

Frequently asked questions

Profiles and related reading

References

1. Jastreboff AM, Kaplan LM, Davies MJ, Wilding JPH, Ahmad NN, Murray M, Du Y, Makarova N, Giblin K, Schloot NC, Wang Y, TRIUMPH-1 Investigators. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. The New England journal of medicine. 2026. doi:10.1056/NEJMoa2604169. PMID:42814954.

   TRIUMPH-1 randomized 2339 adults with obesity without diabetes. At 80 weeks, mean weight reductions ranged 17.6–25.0% with retatrutide versus 3.9% with placebo using the treatment-regimen analysis.

2. Bellido V, le Roux CW, Ekinci EI, Bjornstad P, Frias JP, Giblin K, Eyde S, Park SY, Ferro J, Johnson C, Taylor A. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet (London, England). 2026;408(10563):1455–1472. doi:10.1016/S0140-6736(26)01861-1. PMID:42810372.

   In TRIUMPH-2, 1152 adults with obesity and type 2 diabetes were randomized to retatrutide or placebo. Weight fell more with retatrutide at 80 weeks; digestive events, low blood pressure and altered skin sensations were more frequent.

3. Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, Haupt A, Benson CT, Hernandez-Illas M, D'Alessio DA, Milicevic Z. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet (London, England). 2022;400(10366):1869–1881. doi:10.1016/S0140-6736(22)02033-5. PMID:36354040.

   The 12-week phase 1b trial in type 2 diabetes estimated a retatrutide half-life of approximately six days. The 72-person safety population included 52 retatrutide, 15 placebo and five dulaglutide recipients.

4. Giblin K, Kaplan LM, Somers VK, Le Roux CW, Hunter DJ, Wu Q, Lalonde A, Ahmad N, Bethel MA. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes, Obesity and Metabolism. 2026;28(1):83–93. doi:10.1111/dom.70209. PMID:41090431.

   The design report explains that TRIUMPH used healthy-diet and physical-activity support and nested disease-specific assessments within selected obesity trials. It reports design, not new efficacy results.

5. Eli Lilly and Company. Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. May 21, 2026. Sponsor announcement.

   The sponsor’s 28.3% headline uses an efficacy analysis assuming continued treatment. It differs from the 25.0% treatment-regimen estimate subsequently reported in the published TRIUMPH-1 abstract.

6. Eli Lilly and Company. What to know about retatrutide. Manufacturer development-status information; accessed October 15, 2026.

   The manufacturer identifies retatrutide as investigational and not approved by any regulatory agency, despite completed phase 3 reports.

7. Garvey WT, Blüher M, Osorto Contreras CK, Davies MJ, Winning Lehmann E, Pietiläinen KH, Rubino D, Sbraccia P, Wadden T, Zeuthen N, Wilding JPH, REDEFINE 1 Study Group. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine. 2025;393(7):635–647. doi:10.1056/NEJMoa2502081. PMID:40544433.

   In REDEFINE 1, 3417 adults without diabetes were assigned CagriSema, each component alone or placebo. At 68 weeks, the combination reduced average weight 20.4% versus 3.0% with placebo; digestive events occurred in 79.6% versus 39.9%.

8. Davies MJ, Bajaj HS, Broholm C, Eliasen A, Garvey WT, le Roux CW, Lingvay I, Lyndgaard CB, Rosenstock J, Pedersen SD, REDEFINE 2 Study Group. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. The New England journal of medicine. 2025;393(7):648–659. doi:10.1056/NEJMoa2502082. PMID:40544432.

   REDEFINE 2 randomized 1206 adults with type 2 diabetes and overweight or obesity. Mean weight fell 13.7% with CagriSema versus 3.4% with placebo at 68 weeks; digestive events and treatment stopping were more frequent with the combination.

9. Enebo LB, Berthelsen KK, Kankam M, Lund MT, Rubino DM, Satylganova A, Lau DCW. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021;397(10286):1736–1748. doi:10.1016/S0140-6736(21)00845-X.

   The early coadministration trial measured cagrilintide and semaglutide separately in plasma. Half-life ranges were 159–195 hours and 145–165 hours across groups, and cagrilintide did not materially change semaglutide exposure or elimination.

10. Novo Nordisk. Novo's CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trial. September 21, 2026. Company announcement.

    The sponsor identifies CagriSema as investigational. Its preliminary diabetes and obesity trial summaries concern particular comparisons and amounts; they do not compare CagriSema with retatrutide.